Oppenheimer Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)
Oppenheimer analyst Jay Olson maintained a Buy rating on CymaBay Therapeutics (CBAY) today and set a price target of $6.00. The company’s shares closed last Tuesday at $4.31.
According to TipRanks.com, Olson has 0 stars on 0-5 stars ranking scale with an average return of -7.9% and a 40.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.
CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.03, implying a -12.2% downside from current levels. In a report released yesterday, Raymond James also upgraded the stock to Buy with a $7.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.32 and a one-year low of $1.21. Currently, CymaBay Therapeutics has an average volume of 1.64M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Read More on CBAY: